Foreign direct investment has become one of the quieter but more powerful forces shaping Indian healthcare, steadily building infrastructure, capability, and international credibility across the sector even when it does not make front page news the way a hospital opening or a policy announcement might. Between April 2000 and June 2025, the drugs and pharmaceuticals sector alone received 2,10,940 crore rupees, or roughly 24.62 billion dollars, in cumulative FDI. Hospitals and diagnostic centres attracted a further 12.25 billion dollars, while medical and surgical appliances brought in 3.96 billion dollars, bringing the combined total across these three segments to 40.83 billion dollars, a figure that puts healthcare among the more significant FDI destinations within the broader Indian economy.
A policy framework specifically built to attract this capital
India's investment friendly policy framework has played a large role in attracting this level of capital, and understanding the structure of that framework helps explain why investment has been so sustained rather than sporadic. The country allows 100 percent FDI under the automatic route for greenfield healthcare projects, meaning new hospitals, manufacturing units, and research facilities can be set up with foreign capital without requiring prior government approval, significantly reducing the time and administrative friction involved in launching a new venture. For brownfield investments, where foreign capital is used to acquire or expand an existing facility, up to 100 percent FDI is permitted under the government route, which involves a review process but still allows for full foreign ownership.
This dual structure, automatic approval for new projects and a government reviewed but still generous pathway for acquisitions, gives international investors considerable flexibility in how they choose to enter the Indian market, whether by building from the ground up or by acquiring an established player with existing infrastructure and patient relationships already in place.
Mergers, acquisitions, and private equity activity are accelerating
This capital is not just flowing into large hospital chains through direct greenfield investment, it is also fuelling a wave of mergers, acquisitions, and private equity activity across the sector. Mergers and acquisitions accounted for 57 percent of total deal value in the pharma and healthcare sector during the first quarter of 2025 alone, with private equity making up 59 percent of overall deal volume during the same period. According to the Grant Thornton Bharat Pharma and Healthcare Dealtracker, the sector saw 71 deals worth 22,279 crore rupees, or roughly 2.6 billion dollars, in the first quarter of 2025, with investments focused on scalable global models, speciality pharma, biotech, digital health, and contract research and manufacturing services.
In the third quarter of 2025, healthcare attracted 500 million dollars in private equity and venture capital investment specifically, a figure that, while smaller than the broader M&A totals, reflects continued confidence in the growth potential of earlier stage and mid sized healthcare businesses rather than just established large players.
Global partnerships are bringing more than just capital
Some of this activity is visible in high profile partnerships that go well beyond a simple financial transaction. Apollo Hospitals and the University of Leicester, for example, have established the Centre for Digital Health and Precision Medicine in Chittoor, Andhra Pradesh, an initiative focused on advancing research and education in digital health and precision medicine, seeking to transform healthcare through advances in specialised healthcare programmes. Collaborations of this kind bring not just capital but also global research expertise, academic partnerships, and specialised training capability into the Indian healthcare ecosystem, creating value that extends well beyond the immediate financial investment involved.
Apollo Hospitals has also been active on the domestic consolidation front, announcing in September 2025 that it will acquire a 31 percent stake in Apollo Health and Lifestyle Ltd for 1,254 crore rupees, a deal that, upon completion, will make Apollo Health and Lifestyle a 99.4 percent subsidiary of Apollo Hospitals, illustrating how large domestic players are also using capital, alongside foreign investment, to consolidate and streamline their operations.
What foreign investors are typically looking for
International investors evaluating the Indian healthcare market tend to focus on a fairly consistent set of criteria: scalable business models that can be replicated across multiple cities or regions, exposure to India's demographic growth story, particularly its large and still growing middle class, and increasingly, digital health capabilities that can be layered onto physical infrastructure to improve efficiency and patient experience. Speciality pharma, biotech, and contract research and manufacturing services have also drawn particular attention, reflecting India's established strength in pharmaceutical manufacturing combined with a growing appetite among global players to diversify their supply chains beyond a small number of traditional manufacturing hubs.
What this means for domestic healthcare businesses
For businesses in the sector, this steady flow of foreign investment signals continued confidence in India's long term healthcare growth story. It also means more competition for market share, more capital available for expansion among competitors, and more opportunities for partnerships with international players who are actively looking for a foothold in one of the world's fastest growing healthcare markets. Domestic businesses that position themselves as attractive acquisition targets or partnership candidates, through strong operational track records, scalable models, and clean governance, are well placed to benefit directly from this ongoing wave of foreign capital.
How Indian healthcare compares as an FDI destination against peers
India's position as a healthcare FDI destination is often evaluated by international investors alongside other large emerging markets, particularly China, Southeast Asian markets such as Indonesia and Vietnam, and, for pharmaceutical manufacturing specifically, other established generic drug manufacturing hubs. India's particular advantages in this comparison tend to include its large English speaking, internationally trained medical workforce, an already substantial base of pharmaceutical manufacturing expertise built over decades of generic drug production, and a comparatively transparent and long standing regulatory framework for foreign investment that has been consistently liberalised over time rather than subject to sudden reversals.
Where India faces more competition is on pure cost of manufacturing for very high volume, low complexity production, where some Southeast Asian markets can offer lower labour costs, and on speed of regulatory approval for genuinely novel medical technologies, where some investors still perceive India's approval processes as slower and less predictable than in more established regulatory environments such as the United States or the European Union. Understanding both sides of this comparison helps explain why India has become a particularly strong destination for certain categories of healthcare investment, generic and speciality pharmaceutical manufacturing, hospital chain expansion, and increasingly digital health, while remaining a comparatively smaller player in categories such as cutting edge medical device innovation, where regulatory speed and existing research ecosystems in other countries currently offer a stronger draw.
What continued FDI growth could mean for India's healthcare workforce and pricing
Looking ahead, sustained foreign investment is likely to have effects that extend beyond the immediate capital injection itself. Increased competition among well funded hospital chains, many with foreign backing, tends to push up compensation for skilled medical professionals, since these organisations compete directly for the same limited pool of specialists, particularly in high demand fields such as cardiology and oncology. This can be a double edged development, improving compensation and retention for healthcare workers, which helps address the workforce gap discussed elsewhere on this blog, while also potentially increasing the cost base for hospitals that then need to be reflected somewhere in pricing, whether to patients directly or through insurance premiums. Businesses and policymakers alike are likely to keep a close eye on this dynamic as FDI inflows continue at their current pace, since managing the balance between attracting investment and preserving affordability will remain an ongoing policy consideration.
Frequently asked questions
How much foreign investment has India's healthcare sector received?
India's drugs and pharmaceuticals, hospitals and diagnostic centres, and medical and surgical appliances segments together received 40.83 billion dollars in cumulative FDI between April 2000 and June 2025.
What FDI route applies to new healthcare projects in India?
Greenfield healthcare projects can receive 100 percent FDI under the automatic route, meaning no prior government approval is required, while brownfield investments allow up to 100 percent FDI under the government route.
How active is M&A activity in Indian healthcare?
Mergers and acquisitions accounted for 57 percent of total deal value in the pharma and healthcare sector in the first quarter of 2025, with private equity making up 59 percent of overall deal volume during the same period.
What are international investors looking for in Indian healthcare?
Investors typically focus on scalable business models, exposure to India's growing middle class, speciality pharma and biotech capabilities, contract research and manufacturing services, and digital health integration.
Are Indian hospital groups also active in M&A domestically?
Yes. For example, Apollo Hospitals announced in September 2025 that it would acquire a 31 percent stake in Apollo Health and Lifestyle Ltd, making it a 99.4 percent subsidiary.
Key takeaways
Foreign investment continues to play a defining role in shaping the pace and direction of Indian healthcare's growth, flowing into greenfield projects, acquisitions, and high profile research partnerships alike. For domestic healthcare businesses, this steady capital inflow represents both a source of competitive pressure and a genuine opportunity, particularly for organisations that can present themselves as credible, scalable partners to the international capital actively seeking a foothold in India's healthcare market.
